Full Press Release Details
Provides Business Update and Reports Q4 2025 Financial Results
Calif., April 01, 2026 -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"),
a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today
announced financial results for the quarter and year ended December 31, 2025, and provided an update on recent operational
achievements and upcoming milestones.
Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented:
2025 and early 2026 marked important inflection points for NeOnc. We completed NEO212's Phase 1 dose escalation and established
a recommended Phase 2 dose of 610 mg, with early signs of possible anti-tumor activity in heavily pretreated patients.
parallel, the NEO100 Phase 2a study in recurrent IDH1-mutant high-grade glioma is fully enrolled. Updated Phase 1/2a data suggested
a 24% radiographic remission rate, 44% six-month progression-free survival, and no significant toxicity.
also strengthened the balance sheet through a PIPE financing anchored by Cinctive Capital's $10 million commitment, expanded
the leadership team, and advanced our Middle East strategy through NuroMENA.
ahead, we plan to hold a Type B End-of-Phase 1 FDA meeting for NEO212. We also expect a preliminary NEO100 Phase 2a data readout
in approximately five months. We believe these near-term catalysts position NeOnc to deliver value-creating milestones for shareholders
in the months ahead."
Quarter and Recent Highlights
East Expansion (NuroMENA)
Leadership & Securing Growth Capital
NEONC TECHNOLOGIES HOLDINGS, INC.
Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central
nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's
NEO drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections
extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types
of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100 and NEO212 therapeutics are
in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company
has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued
patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses,
including oncological and neurological conditions.
more about NeOnc and its pioneering technology, visit https://neonc.com.
Cautions Regarding Forward Looking Statements
press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified
by terminology such as "may," "will," "should," "intend," "expect,"
"plan," "budget," "forecast," "anticipate," "believe," "estimate,"
"predict," "potential," "continue," "evaluating," or similar words. Statements
that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations
or financial condition, or other forward-looking information.
refer to the "Risk Factors" section of our Quarterly and annual reports on Form 10-Q and 10-K as filed with the Securities
and Exchange Commission, along with other cautionary language in that report and risk factors and other cautionary language in
our subsequent filings with the Securities and Exchange Commission, outlines important risks and uncertainties. These may cause
our actual results to differ materially from the forward-looking statements herein, including but not limited to the fact that
results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials, announced
or published data from our clinical trials may change as more patient data become available and are subject to audit and verification
procedures that could result in material changes in the final data and our product candidates are in preclinical and clinical stages
of development, are not approved for commercial sale and might never receive regulatory approval or become commercially viable.
assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments,
or otherwise, except as required by applicable securities laws and regulations.
and NEO "212" are registered trademarks of NeOnc Technologies Holdings, Inc.